精选 · 医疗保健

Big pharma

由 InspectStocks 整理Published 2026年10月14日13 companies0 followers

The largest drugmakers, selling prescription medicines worldwide.

借助 AI 模型分组，并经我们的编辑审核。每家公司下方的一行说明它为何在这里。

Download image

卡片梯队

股价为 2026年11月11日收盘价，来自 IEX 交易所数据。

Grade mix

A 7B 3C 3

Revenue growing

12 of 12

Free cash flow growing

9 of 13

Median price move, 1 year

+34.0%

Sort by

LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap US$1.35TP/E 46.67
US$1,437.79+42.2%1Y
Since added +23.2%
A+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$86.5B+45.5%
Profit
US$27.6B+49.8%
Free cash flow
US$19.7B+112.1%
Discuss
Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
JNJJohnson & Johnson
Drug manufacturers generalMarket cap US$674.9BP/E 42.54
US$280.34+47.5%1Y
Since added +12.8%
A+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
参差
Revenue
US$99.3B+7.8%
Profit
US$16.1B-35.9%
Free cash flow
US$20.6B+5.1%
Discuss
Why it is here: Sells prescription medicines for cancer and immune disorders
ABBVAbbVie Inc.
Drug manufacturers generalMarket cap US$521.2BP/E 50.75
US$294.87+30.2%1Y
Since added +7.5%
B+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$66B+10.7%
Profit
US$10.3B+333.1%
Free cash flow
US$18.9B-4.1%
Discuss
Why it is here: Sells medicines for immune, neurological and cancer conditions
MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap US$362.9BP/E 150.20
US$147.20+65.7%1Y
Since added +3.7%
A
成长与现金
强劲增长
Business trend
平稳
Business quality
稳健
Getting better
参差
Revenue
US$67.4B+4.9%
Profit
US$2.5B-87.1%
Free cash flow
US$14.7B+13.0%
Discuss
Why it is here: Sells prescription medicines and vaccines for people and animals
NVSNovartis AG
Drug manufacturers generalMarket cap US$306B无市盈率（经营亏损）
US$160.36+23.6%1Y
Since added +12.6%
A
成长与现金
强劲增长
Business quality
参差
Getting better
明显改善
Revenue
US$56.7B+9.6%
Profit
-US$46MNo comparable year
Free cash flow
US$17.6B+8.3%
Discuss
Why it is here: Sells prescription medicines
AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap US$289.7BP/E 28.36
US$185.49+115.2%1Y
Since added +19.0%
B+
成长与现金
强劲增长
Business trend
放缓
Business quality
强
Getting better
明显改善
Revenue
US$62.4B+7.3%
Profit
US$10.2B+45.3%
Free cash flow
US$11.8B+18.4%
Discuss
Why it is here: Sells prescription medicines
NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap US$182.8BP/E 11.84
US$41.10-15.4%1Y
Since added +8.0%
C+
成长与现金
在增长
Business trend
加速
Business quality
强
Getting better
在改善
Revenue
US$50.3B+5.7%
Profit
US$17.1B+9.1%
Free cash flow
US$8.9B-20.1%
Discuss
Why it is here: Sells diabetes and obesity medicines
PFEPFIZER INC
Drug manufacturers generalMarket cap US$167.9BP/E 42.07
US$29.45+21.4%1Y
Since added +3.8%
C
成长与现金
强劲增长
Business trend
收缩
Business quality
稳健
Getting better
参差
Revenue
US$63.6B+1.3%
Profit
US$4B-59.0%
Free cash flow
US$11.8B+13.6%
Discuss
Why it is here: Sells prescription medicines and vaccines
BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap US$128.6BP/E 13.95
US$62.92+34.0%1Y
Since added +11.0%
C+
成长与现金
在增长
Business trend
平稳
Business quality
强
Getting better
明显改善
Revenue
US$50B+4.2%
Profit
US$9.2B+53.1%
Free cash flow
US$9.3B-39.3%
Discuss
Why it is here: Sells prescription medicines for cancer and immune conditions
SNYSanofi
Drug manufacturers generalMarket cap US$59.1BP/E 6.81
US$48.43-3.0%1Y
Since added +23.9%
B
成长与现金
强劲增长
Business trend
平稳
Business quality
参差
Getting better
在改善
Revenue
US$53.5B+11.6%
Profit
US$4.7B-54.2%
Free cash flow
US$8.1B+22.5%
Discuss
Why it is here: Sells prescription medicines and vaccines
GSKGSK plc
Drug manufacturers generalMarket cap US$109.2BP/E 13.60
US$50.60+8.9%1Y
Since added +9.3%
A+
成长与现金
强劲增长
Business quality
强
Getting better
明显改善
Revenue
US$43.8B+4.1%
Profit
US$7.7B+122.0%
Free cash flow
US$8.6B+24.0%
Discuss
Why it is here: Sells prescription medicines and vaccines worldwide
AMGNAmgen Inc.
Drug manufacturers generalMarket cap US$253.2BP/E 27.14
US$468.13+43.1%1Y
Since added +13.4%
A+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$38.9B+8.2%
Profit
US$9.4B+34.1%
Free cash flow
US$9.6B-17.0%
Discuss
Why it is here: Develops and sells medicines and biosimilars for serious diseases
TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap US$33.5BP/E 48.79
US$20.86+50.1%1Y
Since added +12.5%
A
成长与现金
强劲增长
Business quality
参差
Getting better
参差
Revenue
US$29.8BNo comparable year
Profit
US$259.4MNo comparable year
Free cash flow
US$5.5B+1.1%
Discuss
Why it is here: Sells prescription medicines and vaccines globally

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.